in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
FDA Charges Ranbaxy with Falsifying Data at India Plant
11:11 AM MST | March 6, 2009 | DEEPTI RAMESH
The U.S. FDA has charged Ranbaxy Laboratories (Gurgaon, India) with falsifying data and test results in approved and pending drug applications at the company’s Paonta Sahib, India facility. The agency says it has stopped reviewing new or pending drug approval applications from the plant, which has been under an FDA import alert since last September for deviating from U.S. cGMP (CW, Sept. 22, 2008, p. 4). Ranbaxy says it will co-operate with FDA. Woodcock: ‘Companies must provide truthful and accurate information.’ Applications that are affected...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee